Basildon, UK, March 2014 – Atnahs Pharma UK Limited (“Atnahs”) is delighted to announce that, as part of its on-going strategy of developing the business we have completed the acquisition of Dipentum® from UCB Pharma Limited, effective from 1st January 2014.
Dipentum® is an oral treatment for mild active ulcerative colitis and the maintenance of remission. It is the second significant acquisition that Atnahs has made since its inception and sits neatly into the existing portfolio of niche established branded therapeutic medicines.
Bhikhu Patel, founder and co-chairman, comments,
“The acquisition of Dipentum®, so soon after the purchase of the Marlborough portfolio, demonstrates the determination and drive of the Atnahs team to build on their extensive experience. Dipentum® is Atnahs’ first international acquisition, represented in 14 countries including Australia, Canada, South Africa and mainland Europe. ”
Mark Cotterill, Group CEO further comments,
“The team will now be focused on working with UCB and transitioning the products across all of the markets into our international distribution network to ensure the seamless provision of Dipentum®.”
Atnahs is a family owned pharmaceutical business, created by the management team which established, developed and sold Amdipharm Plc to Cinven in November 2012 for £367m.
Atnahs’ Management Team is leveraging its depth of experience and heritage to create a new platform for growth. International acquisitions of niche established branded medicines coupled with a pipeline of niche generic medicines developed in our own facility form the core of our strategy.